Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Magliocco on Pathologists in the Treatment of Melanoma

October 10th 2013

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

Dr. Hamid on Immune Therapy in Melanoma

October 8th 2013

Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.

Redheads and Melanoma

October 7th 2013

Underlying mechanism for increased risk now defined.

Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

October 4th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab

October 2nd 2013

Results from a pooled analysis of data from 12 studies has demonstrated a long-term survival benefit that extends through at least 10 years for patients with advanced melanoma treated with ipilimumab.

Dr. Hudis on the Optimism Surrounding Immunotherapy

September 27th 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Dr. Carvajal on the Design of a Trial in Uveal Melanoma

September 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.

Dr. Sosman on the Mechanism of Action of Ipilimumab

September 24th 2013

Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.

Dabrafenib and Trametinib Combination Granted Priority Review Designation by FDA

September 16th 2013

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

Dr. Gulley Discusses Vaccine Responses

September 10th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

Investigational Vaccine Fails to Extend Disease-Free Survival in Certain Patients with Advanced Melanoma

September 5th 2013

The investigational MAGE-A3 immunotherapeutic did not significantly extend disease-free survival (DFS) in certain patients with postsurgical melanoma when compared with a placebo in a phase III study.

Novel Agents Revolutionize Melanoma Treatment

September 5th 2013

Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-Î± (IFN-Î±).

Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer

August 28th 2013

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Study Shows Benefit of High-Dose IL-2 in Melanoma Brain Metastases

August 23rd 2013

High doses of interleukin-2 could be used to treat patients with melanoma whose disease has metastasized to the brain, potentially expanding options in a population facing a grim prognosis.

Dr. Parsa on the Administration of the G-200 Vaccine in GBM

August 21st 2013

Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.

Dr. Schuchter Discusses Nivolumab in Melanoma

August 21st 2013

Lynn M. Schuchter, MD, from the University of Pennsylvania, describes two trials presented at the 2013 ASCO Meeting looking at nivolumab in patients with melanoma.

Nivolumab Benefits Durable in Three Tumor Types

August 19th 2013

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Study Details Adverse Events in Pivotal Ipilimumab Trial

August 16th 2013

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

Allovectin Falters in Late-Stage Melanoma Trial

August 13th 2013

Nearly two decades after clinical trials began, the investigational immunotherapy Allovectin failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma and will no longer be developed.

Lambrolizumab Demonstrates Significant Antitumor Activity in Melanoma

August 8th 2013

The investigational antibody lambrolizumab demonstrated significant antitumor activity and good response rates as well as a tolerable toxicity profile in patients with melanoma.